Skip to main content

Table 5 Univariate and Multivariate analysis of PFS

From: Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

  Cases     Univariate Multivariate
   1-yr survival rate(%) 2-yr survival rate(%) Median survival(mo) P-Value ExpB (Hazard Ratio ,95 % CI) P-Value
Gender        
 Male 130 47 26 10.79 0.331   
 Female 12 37 0 6.11    
Age        
  < 60 92 49 29 10.49 0.180   
  ≥ 60 50 40 21 9.35    
Alpha-foetoprotein(ng/ml)        
  ≤ 20 42 50 44 11.99 0.445   
 20–400 37 35 8 7.03    
  ≥ 400 63 51 28 8.37    
Child Pugh grade      0.047 2.852(1.002–8.293) 0.050
 A 133 48 28 10.56    
 B 9 22 0 7.07    
ALB(g/L)      0.307   
  ≥ 35 108 46 20 10.49    
  < 35 34 47 47 10.25    
Tbil(U/L)      0.429   
  < 20 104 49 23 11.18    
  ≥ 20 38 37 32 6.21    
Platelet count (10E9/L)        
  < 100 19 74 32 13.57 0.144   
  ≥ 100 123 42 25 9.83    
No. of tumours      0.034 3.992(1.978–8.057) 0.001
  ≤ 3 118 51 28 11.04    
  > 3 24 21 14 7.6    
Tumour size (cm)      0.988 2.667(1.041–6.832) 0.041
  ≤ 5 35 39 24 11.37    
  > 5 107 48 25 8.37    
Virus infection      0.079   
 none 14 59 59 13.05    
 HBV 126 43 24 10.25    
 HCV 2 50 0 11.30    
Anti-virus therapy      0.951   
 Yes 33 44 30 8.37    
 No 95 43 22 10.56    
H101      0.051 0.461(0.244–0.870) 0.017
 Yes 74 51 32 10.49    
 No 68 41 20 9.72